风湿性二尖瓣病变手术中联合切缝迷宫III术的前瞻性随机试验
该前瞻性随机试验将130例风湿性二尖瓣病变合并持续性或长程持续性房颤患者随机分为迷宫III联合二尖瓣置换组与单纯二尖瓣置换组。主要终点为1年无卒中和死亡复合终点。HR=0.2653;95%CI 0.1122-0.6270),且不增加手术风险。
要点
- 两组主要并发症和院内死亡率无显著差异
核心结论
- 在二尖瓣置换术中加做切缝迷宫III术可降低风湿性二尖瓣病变合并房颤患者1年卒中或死亡风险并提高窦性心律维持率,且不增加手术风险。
研究设计与样本
- 前瞻性随机对照试验,共纳入130例风湿性二尖瓣病变合并持续性或长程持续性房颤患者,随机分为迷宫III联合二尖瓣置换组与单纯二尖瓣置换组。
主要发现
- 迷宫III组与非迷宫组在主要并发症和院内死亡率方面无显著差异。
关键数值与推荐
- 主要终点为1年无卒中和死亡复合终点。
临床怎么用
- 对风湿性二尖瓣病变合并持续性或长程持续性房颤行二尖瓣置换的患者,可考虑同期加做切缝迷宫III术以改善1年无卒中或死亡结局并降低房颤复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and efficacy of the addition of the cut-and-sew Maze III procedure (CSM) for mitral valve replacement (MVR) in patients with atrial fibrillation (AF) associated with rheumatic mitral valve disease (RMVD). METHODS: A total of 130 patients with persistent or long-standing persistent AF associated with RMVD were assigned at random to either the CSM plus MVR (Maze III) group or MVR alone (non-Maze) group. The primary endpoint was a composite of freedom from stroke and death at 1 year. RESULTS: There were no significant differences between the Maze III and non-Maze groups in terms of major complications and in-hospital mortality. One-year freedom from stroke or death was better in the Maze III group compared with the non-Maze group (P = .0028; hazard ratio, 0.2653; 95% confidence interval, 0.1122 to 0.6270). The risk of AF recurrence in the Maze III group was 0.002-fold that in non-Maze group (P = .000). CONCLUSIONS: Addition of the CSM to an MVR procedure can decrease the risk of stroke or death and high sinus rhythm at 1 year without increasing the operative risk. CSM is a safe and effective approach to treating AF associated with RMVD.
引用
- Wang H, Han J, Wang Z, et al. A prospective randomized trial of the cut-and-sew Maze procedure in patients undergoing surgery for rheumatic mitral valve disease. J Thorac Cardiovasc Surg. 2017. PMID: 28965725. doi:10.1016/j.jtcvs.2017.07.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。